These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3025124)

  • 1. Cardiovascular alterations in the rabbit infused with platelet activating factor (PAF): effect of kadsurenone, a PAF-receptor antagonist.
    Montrucchio G; Alloatti G; Mariano F; Tetta C; Emanuelli G; Camussi G
    Int J Tissue React; 1986; 8(6):497-504. PubMed ID: 3025124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor.
    Shen TY; Hwang SB; Chang MN; Doebber TW; Lam MH; Wu MS; Wang X
    Int J Tissue React; 1985; 7(5):339-43. PubMed ID: 2997065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
    Hwang SB; Li CL; Lam MH; Shen TY
    Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: in vivo pharmacological studies.
    Castro-Faria-Neto HC; Araújo CV; Moreira S; Bozza PT; Thomas G; Barbosa-Filho JM; Cordeiro RS; Tibiriçá EV
    Planta Med; 1995 Apr; 61(2):106-12. PubMed ID: 7753914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of kadsurenone analogues.
    Ponpipom MM; Bugianesi RL; Brooker DR; Yue BZ; Hwang SB; Shen TY
    J Med Chem; 1987 Jan; 30(1):136-42. PubMed ID: 3027330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects.
    Shen TY; Hwang SB; Chang MN; Doebber TW; Lam MH; Wu MS; Wang X; Han GQ; Li RZ
    Proc Natl Acad Sci U S A; 1985 Feb; 82(3):672-6. PubMed ID: 2983307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species difference in the specific receptors of platelet activating factor.
    Hwang SB; Lam MH
    Biochem Pharmacol; 1986 Dec; 35(24):4511-8. PubMed ID: 3024653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
    J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific binding of [3H]dihydrokadsurenone to rabbit platelet membranes and its inhibition by the receptor agonists and antagonists of platelet-activating factor.
    Hwang SB; Lam MH; Chang MN
    J Biol Chem; 1986 Oct; 261(29):13720-6. PubMed ID: 3020044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
    Fernández-Gallardo S; Ortega MP; Priego JG; de Casa-Juana MF; Sunkel C; Sánchez Crespo M
    J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC; Seldon PM; Barnes PJ; Giembycz MA
    Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone.
    Doebber TW; Wu MS; Robbins JC; Choy BM; Chang MN; Shen TY
    Biochem Biophys Res Commun; 1985 Mar; 127(3):799-808. PubMed ID: 2985058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of SRI 63-675, a competitive platelet-activating factor receptor-antagonist, in the generalized Shwartzman reaction.
    Gans RO; DiPirro JC; Ueda Y; Niesen N; Lee KH; Brentjens JR
    J Lipid Mediat Cell Signal; 1994 Sep; 10(3):229-42. PubMed ID: 7812674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion.
    Ko W; Lang D; Hawes AS; Zelano JA; Isom OW; Krieger KH
    J Surg Res; 1993 Nov; 55(5):504-15. PubMed ID: 8231170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-mediated and protein kinase-dependent growth enhancement of primary human fibroblasts by platelet activating factor.
    Bennett SA; Birnboim HC
    Mol Carcinog; 1997 Dec; 20(4):366-75. PubMed ID: 9433481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiinflammatory and antiallodynic actions of the lignan niranthin isolated from Phyllanthus amarus. Evidence for interaction with platelet activating factor receptor.
    Kassuya CA; Silvestre A; Menezes-de-Lima O; Marotta DM; Rehder VL; Calixto JB
    Eur J Pharmacol; 2006 Sep; 546(1-3):182-8. PubMed ID: 16925995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased platelet-activating factor receptor gene expression by corneal epithelial wound healing.
    Ma X; Bazan HE
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1696-702. PubMed ID: 10845588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kadsurenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes.
    Lambrecht G; Parnham MJ
    Br J Pharmacol; 1986 Feb; 87(2):287-9. PubMed ID: 3006857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.